Stockscreener 앱 받기
148.03
0.65%
1.01
전일 마감가:
$147.02
열려 있는:
$146.1
하루 거래량:
697.69K
Relative Volume:
0.60
시가총액:
$14.88B
수익:
$2.86B
순이익/손실:
$478.60M
주가수익비율:
31.71
EPS:
4.6676
순현금흐름:
$748.70M
1주 성능:
+12.38%
1개월 성능:
+13.04%
6개월 성능:
-2.89%
1년 성능:
+21.68%
1일 변동 폭
$146.08
$149.53
1주일 범위
$129.86
$149.53
52주 변동 폭
$115.66
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
147.98 | 14.78B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 52.82B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.78 | 42.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.3101 | 40.97B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
88.54 | 46.77B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
572.10 | 25.33B | 3.18B | 1.33B | 1.04B | 27.90 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine Biosciences Stock 8-Day Winning Spree: Stock Climbs 15% - Trefis
Neurocrine Biosciences (NBIX) Earnings Surge Challenges Cautious Narratives On Margin Durability - simplywall.st
Research Alert: CFRA Keeps Hold Rating On Shares Of Neurocrine Biosciences Inc. - 富途牛牛
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside - Seeking Alpha
Truist raises Neurocrine Bio stock price target on strong sales By Investing.com - Investing.com Canada
Is Neurocrine Biosciences (NBIX) Pricing In Too Much Caution After Recent Share Gains? - Yahoo Finance
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia - BioSpace
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY - StreetInsider
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript - Insider Monkey
Oppenheimer raises Neurocrine Bio stock price target on strong results By Investing.com - Investing.com Australia
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
MSN Money - MSN
Research Alert: Nbix Q1 Tops Estimates, Strategic Acquisition To Boost Rare Disease Portfolio - Moomoo
Neurocrine Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Neurocrine Biosciences Q1 Earnings Call Highlights - Yahoo Finance
Neurocrine Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NBIX) 2026-05-05 - Seeking Alpha
Neurocrine Q1 2026 slides: revenue surges 44% on dual-product strength - Investing.com
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat By Investing.com - Investing.com Australia
Neurocrine Biosciences : Presentation (NBIX Q1 2026 Earnings Presentation Final 0556) - marketscreener.com
Neurocrine Biosciences (NBIX) Valuation Check After New Long Term CRENESSITY Phase 3 Data - simplywall.st
Neurocrine (NBIX) Q1 2026 Earnings Transcript - AOL.com
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat - Investing.com
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Neurocrine Biosciences surges 8% as INGREZZA sales drive better-than-expected Q1 results - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Smashes Q1 Estimates with 44% Sales Surge - ChartMill
Neurocrine Biosciences Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Neurocrine: Q1 Earnings Snapshot - marketscreener.com
Neurocrine Biosciences (NBIX) posts strong Q1 2026 results and plans $2.9B Soleno deal - Stock Titan
Big Q1 2026 jump as Neurocrine (NASDAQ: NBIX) inks $2.9B Soleno buy - Stock Titan
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results - Santa Maria Times
Neurocrine in the spotlight: Can growth justify Soleno bet? By Investing.com - Investing.com UK
Neurocrine executives take Bank of America health conference stage - Stock Titan
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 - PR Newswire
Neurocrine Biosciences Inc (NBIX) - MSN
Neurocrine begins phase 1 trial of obesity drug NBIP-2118 By Investing.com - Investing.com Australia
Should Durable Two-Year CRENESSITY CAH Data Shift Neurocrine Biosciences’ (NBIX) Long-Term Investment Narrative? - simplywall.st
Survey: adults with tardive dyskinesia missed 8 work hours a week - Stock Titan
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment - PR Newswire
Neurocrine begins phase 1 trial of obesity drug NBIP-2118 - Investing.com
Neurocrine Biosciences announces initiation of phase 1 clinical study evaluating NBIP-'2118, a corticotropin-releasing factor type 2 receptor agonist - marketscreener.com
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Uncovering a Potential 40.88% Upside in the Healthcare Sector - DirectorsTalk Interviews
Trading Systems Reacting to (NBIX) Volatility - Stock Traders Daily
Horizon Investments LLC Buys 16,474 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Will Two-Year CRENESSITY Data in CAH Change Neurocrine Biosciences' (NBIX) Narrative? - Yahoo Finance
Neurocrine’s Two Year CAH Data May Reframe NBIX Valuation Story - simplywall.st
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Up 23.9% in April - MarketBeat
Neurocrine presents two-year data on CAH treatment Crenessity - Investing.com UK
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,133 |
0 |
39,230 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
3,352 |
0 |
7,969 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
1,600 |
0 |
6,313 |
| Gano Kyle | Chief Executive Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,807 |
0 |
147,610 |
| Gano Kyle | Chief Executive Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
4,907 |
0 |
146,661 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
5,407 |
0 |
21,066 |
| Onyia Jude | Chief Scientific Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,560 |
0 |
18,537 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,044 |
0 |
56,664 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,005 |
0 |
54,760 |
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
2,911 |
0 |
30,395 |
0.33%
0.59%
자본화:
|
볼륨(24시간):